DE69814691T2 - Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten - Google Patents

Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten

Info

Publication number
DE69814691T2
DE69814691T2 DE69814691T DE69814691T DE69814691T2 DE 69814691 T2 DE69814691 T2 DE 69814691T2 DE 69814691 T DE69814691 T DE 69814691T DE 69814691 T DE69814691 T DE 69814691T DE 69814691 T2 DE69814691 T2 DE 69814691T2
Authority
DE
Germany
Prior art keywords
treatment
angiogenic diseases
ingiogenese
treating cancer
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69814691T
Other languages
English (en)
Other versions
DE69814691D1 (de
Inventor
E Wuthier
Daotai Nie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina filed Critical University of South Carolina
Publication of DE69814691D1 publication Critical patent/DE69814691D1/de
Application granted granted Critical
Publication of DE69814691T2 publication Critical patent/DE69814691T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69814691T 1997-11-21 1998-11-18 Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten Expired - Lifetime DE69814691T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,813 US5932611A (en) 1997-11-21 1997-11-21 Angiogenesis inhibitor for the treatment of cancer
PCT/US1998/024645 WO1999026622A1 (en) 1997-11-21 1998-11-18 Use of fc101 as an angiogenesis inhibitor for the treatment of cancer and other angiogenic diseases

Publications (2)

Publication Number Publication Date
DE69814691D1 DE69814691D1 (de) 2003-06-18
DE69814691T2 true DE69814691T2 (de) 2003-11-27

Family

ID=25523430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814691T Expired - Lifetime DE69814691T2 (de) 1997-11-21 1998-11-18 Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten

Country Status (6)

Country Link
US (5) US5932611A (de)
EP (1) EP1049463B1 (de)
AT (1) ATE240100T1 (de)
AU (1) AU749021B2 (de)
DE (1) DE69814691T2 (de)
WO (1) WO1999026622A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932611A (en) * 1997-11-21 1999-08-03 University Of South Carolina Angiogenesis inhibitor for the treatment of cancer
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
KR100675252B1 (ko) * 2000-03-08 2007-02-08 한국생명공학연구원 신규 7,8-디히드로-잔테논-8-카르복실산 유도체 및 이를생산하는 신규 미생물
US6844705B2 (en) * 2002-12-09 2005-01-18 Intersil Americas Inc. Li-ion/Li-polymer battery charger configured to be DC-powered from multiple types of wall adapters
WO2004103985A2 (en) * 2003-05-16 2004-12-02 University Of South Carolina Derivatives of fusarochromanone as therapeutic agents
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US8852925B2 (en) * 2007-12-17 2014-10-07 The Charlotte-Mecklenburg Hospital Authority Bioreactor for cell growth and associated methods
US8344020B2 (en) * 2008-04-11 2013-01-01 University Of South Carolina Use of fusarochromanone and its derivatives in the diagnosis and treatment of cancer and other diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5932611A (en) * 1997-11-21 1999-08-03 University Of South Carolina Angiogenesis inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
US6660765B2 (en) 2003-12-09
US7078433B2 (en) 2006-07-18
EP1049463A1 (de) 2000-11-08
WO1999026622A1 (en) 1999-06-03
EP1049463B1 (de) 2003-05-14
US6225340B1 (en) 2001-05-01
DE69814691D1 (de) 2003-06-18
AU1418899A (en) 1999-06-15
US20030083370A1 (en) 2003-05-01
US20040092580A1 (en) 2004-05-13
ATE240100T1 (de) 2003-05-15
AU749021B2 (en) 2002-06-13
US5932611A (en) 1999-08-03
US20010011100A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
IS6647A (is) Kínasólínafleiður til að meðhöndla æxli
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69535805D1 (de) Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz
ATE265456T1 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
IL142066A0 (en) Arylsulfonanilide urea derivatives and pharmaceutical compositions containing the same
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
DK0972517T3 (da) Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
PT939627E (pt) Pentafluorobenzenossulfonamidas e analogos
DE69622871D1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
NO994330L (no) Metode for behandling av en tumor
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE69814691T2 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
DE60011794D1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера

Legal Events

Date Code Title Description
8364 No opposition during term of opposition